Derek Maetzold Sells 20,356 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 20,356 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $31.11, for a total transaction of $633,275.16. Following the sale, the insider owned 21,479 shares of the company’s stock, valued at approximately $668,211.69. The trade was a 48.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $32.03 on Friday. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $23.77 and its 200 day simple moving average is $26.20. The company has a market cap of $978.52 million, a price-to-earnings ratio of -48.53 and a beta of 0.98.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The business had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Sell-side analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

CSTL has been the topic of a number of recent research reports. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research note on Friday, May 29th. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Canaccord Genuity Group dropped their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Robert W. Baird set a $36.00 price target on Castle Biosciences in a report on Friday, July 31st. Finally, BTIG Research lifted their price target on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Key Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and indicates potential upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest earnings exceeded expectations. Revenue was $99.86 million versus the $86.23 million consensus estimate, while the company reported a per-share loss of $0.07 compared with the expected $0.41 loss. Although CSTL remains unprofitable, the narrower-than-expected loss and stronger revenue support an improving operating outlook.
• Neutral Sentiment: Institutional investors own approximately 92.6% of CSTL’s shares. Recent purchases or stake increases by firms including AQR Capital Management, Amundi, Legal & General and Mirae Asset may provide shareholder support, but these ownership changes are not necessarily immediate trading catalysts.
• Negative Sentiment: Several company insiders disclosed sizable stock sales. Derek J. Maetzold sold more than 39,000 shares for approximately $1.21 million in August 4–5 transactions, while COO Kristen Oelschlager sold 8,586 shares worth about $256,000. Tobin W. Juvenal separately sold 1,301 shares for roughly $50,000. The sales reduced the insiders’ positions and could pressure sentiment, particularly following CSTL’s recent advance. However, all of the reported transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them a less definitive bearish signal. Castle Biosciences insider sales

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently bought and sold shares of the company. Summit Partners Public Asset Management LLC boosted its holdings in Castle Biosciences by 164.7% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares during the period. SummitTX Capital L.P. increased its holdings in shares of Castle Biosciences by 285.0% in the first quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock worth $1,646,000 after purchasing an additional 49,623 shares during the period. Eventide Asset Management LLC purchased a new stake in shares of Castle Biosciences in the fourth quarter worth $11,864,000. KBC Group NV bought a new stake in Castle Biosciences during the first quarter valued at $907,000. Finally, SG Americas Securities LLC boosted its stake in Castle Biosciences by 1,051.8% during the first quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock valued at $6,012,000 after buying an additional 223,624 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.